MDXG - MiMedx Corp Total Debt to Capital

Public company logo of MiMedx Group, Inc. (MDXG)

MiMedx Group, Inc. operates a resilient regenerative medicine business that remains independent of seasonality or market downturns. Strong physician confidence in placental technologies strengthens the brand's position. The debt-to-equity ratio reflects the financial leverage, where 0.00 represents the current level of the metric. Growth prospects are supported by the implementation of robotic biomaterial processing lines and packaging automation.

MDXG: MiMedx Total Debt to Capital 07/04/2022 - 10/30/2026
Core merchandise of MiMedx Corp

Assessing the financial stability of MiMedx Group, Inc. (MDXG) requires an analysis of the debt load to determine default risks. Maintaining a closed-loop regenerative medicine cycle requires significant capital expenditures in proprietary technologies. The total financial debt-to-equity ratio measures the proportion of borrowed funds relative to the business's own equity. An increase in this metric signals excessive credit dependence, while a decrease indicates conservative management. This chart allows for an assessment of the balance between growth leverage and the company's solvency.

Competitor analysis for MiMedx Group, Inc.

Debt to Equity Ascendis Pharma|Madrigal Pharmaceuticals Inc - Aggregate Debt to Equity|Total Debt to Capital CORT|RYTM (Rhythm Corp) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital AKRO (Akero Therapeutics)|Total Debt to Capital metsera.com MTSR|MLTX - Debt to Equity|All Debt to Shareholders' Equity Ratio CRNX (Crinetics Pharmaceuticals, Inc.)|NewAmsterdam Pharma N.V. (NAMS) - Debt to Equity|Total Debt to Equity Ratio Soleno Therapeutics Corp|FOLD (Amicus Therapeutics) - Total Debt to Capital|Total Debt to Capital 89bio.com|Total Debt to Equity Ratio AGIO (Agios Pharmaceuticals, Inc.)|GPCR (Structure Therapeutics Inc) - All Debt to Shareholders' Equity Ratio|Debt to Equity Rezolute Corp RZLT|LXRX - Total Debt to Equity Ratio|MBX Biosciences Inc - Total Debt to Capital|Debt to Capital altimmune.com|AARD (Aardvark Therapeutics) - Total Debt to Equity Ratio|SGMT: Aggregate Debt to Capital|BIOA (BioAge Labs Inc.) - Total Debt to Capital|Total Debt to Capital Biomea Fusion Corp|Total Debt to Capital QNCX|Debt to Equity GUTS (fractyl.com)|Debt to Equity vTv Therapeutics VTVT|Agape ATP Corp (ATPC) - Debt to Capital|PLUR - Debt to Equity|SYBX: Debt to Equity|LPCN: Total Debt to Capital|MTNB - Total Debt to Capital Coefficient|Debt to Equity Spruce Biosciences, Inc.|Galecto Inc (GLTO) - Total Debt to Capital Coefficient|Debt to Equity Carmell Corp (CTCX)|Total Debt to Equity Ratio Lumos Therapeutics LUMO|Debt to Equity Organovo Holdings, Inc. ONVO|RDUS - Total Debt to Equity Ratio